Drug Alert: CDSCO flags 64 drug samples including Aristo's Monocef 500

In its latest drug safety alert, the apex drug regulatory body, the Central Drugs Standard Control Organization (CDSCO) has flagged 62 medicine batches for failing to qualify for a random drug sample test for November– 2023, while two drug samples have been declared misbranded and spurious.

These drug samples which are declared not of standard quality include Meropenem Injection IP 0.5 g manufactured by Bharat Parenterals, Artesunate injection IP (Zynate) manufactured by Jackson Laboratories, Montelukast Sodium and Levocetirizine Hydrochloride Tablets I.P. manufactured by Unicure India, Ciprofloxacin tablets I.P. 500 mg manufactured by ANG Lifesciences India, Glimepiride tablets I.P. 1 mg manufactured by Apple Formulations and others.

For more details, check out the link given below:

CDSCO Drug Alert: 64 Drug Samples Including Aristo's Monocef 500 Flagged